Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

Shares of DexCom Inc. rallied 7.22% to $77.98 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.51% to 7,533.77 and Dow Jones ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. DexCom (DXCM) is a stock that can certainly grab the attention of ...

The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 diabetes using insulin therapy, as well as certain non-insulin users who ...

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the ...

Shares of DexCom Inc. DXCM shed 1.71% to $76.65 Friday, on what proved to be an all-around poor trading session for the stock ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...